What pharmacological agents are used in the treatment of DI, and how do they work?

Indunil Karunarathna @Indunil-Karunarathna

09 May 2024 1 9K Report

What pharmacological agents are used in the treatment of DI, and how do they work?Article Advances in Understanding and Management of Antidiuretic Hor...

Indunil Karunarathna

Article Advances in Understanding and Management of Antidiuretic Hor...

The pharmacological treatment of Diabetes Insipidus (DI) aims to replace deficient antidiuretic hormone (ADH) or enhance renal responsiveness to ADH, depending on the type of DI (central or nephrogenic). Here are the pharmacological agents commonly used in the treatment of DI and how they work:

Desmopressin (DDAVP):Mechanism: Desmopressin is a synthetic analog of vasopressin (ADH) with enhanced antidiuretic activity and longer duration of action. It acts on V2 receptors in the renal collecting ducts to increase water reabsorption and decrease urine output. Indication: Desmopressin is the primary treatment for central DI (neurogenic DI) due to deficiency or inadequate secretion of ADH. It can also be used to manage nocturnal enuresis (bedwetting) and primary nocturnal polyuria. Administration: Desmopressin is available in various formulations, including intranasal spray, subcutaneous injection, oral tablets, and intravenous infusion. The intranasal route is commonly used for chronic management of DI, while injectable formulations are reserved for acute or severe cases. Monitoring: Close monitoring of fluid intake, urine output, and serum sodium levels is necessary during desmopressin therapy to prevent overcorrection of hyponatremia and minimize the risk of water intoxication.

Thiazide Diuretics:Mechanism: Thiazide diuretics (e.g., hydrochlorothiazide) enhance renal tubular reabsorption of sodium and water in the distal convoluted tubule, leading to decreased urine output and increased urine osmolality. In nephrogenic DI, thiazides induce mild volume depletion, which paradoxically enhances proximal tubular water reabsorption and reduces polyuria. Indication: Thiazide diuretics are used to manage nephrogenic DI, particularly in cases with partial renal responsiveness to ADH. They are often used in combination with a low-sodium diet to enhance their antidiuretic effects. Monitoring: Monitoring of serum electrolytes, renal function, and urine output is necessary during thiazide therapy to prevent electrolyte imbalances and assess treatment response.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs):Mechanism: NSAIDs (e.g., indomethacin) inhibit renal prostaglandin synthesis, which may reduce renal blood flow and enhance proximal tubular water reabsorption, leading to decreased urine output and increased urine osmolality. NSAIDs are thought to exert their antidiuretic effects by counteracting the vasodilatory and diuretic effects of prostaglandins in the kidney. Indication: NSAIDs may be used as adjunctive therapy in nephrogenic DI, particularly in cases associated with elevated urinary prostaglandin levels or partial renal responsiveness to ADH. Monitoring: Monitoring of renal function, serum electrolytes, and gastrointestinal symptoms (e.g., gastritis, peptic ulcer disease) is necessary during NSAID therapy to prevent adverse effects and assess treatment response.

Amiloride:Mechanism: Amiloride is a potassium-sparing diuretic that inhibits sodium reabsorption in the distal nephron, leading to mild diuresis and reduced potassium excretion. In nephrogenic DI, amiloride may reduce urine volume and increase urine osmolality by blocking epithelial sodium channels (ENaC) in the collecting ducts. Indication: Amiloride may be used as adjunctive therapy in nephrogenic DI, particularly in cases associated with hypokalemia or metabolic alkalosis. Monitoring: Monitoring of serum potassium levels, renal function, and blood pressure is necessary during amiloride therapy to prevent hyperkalemia and assess treatment response.

The choice of pharmacological agent for the treatment of DI depends on various factors, including the type of DI (central or nephrogenic), underlying etiology, severity of symptoms, and patient-specific considerations. Treatment should be individualized, with close monitoring of fluid intake, urine output, serum electrolytes, and response to therapy to optimize patient outcomes and minimize the risk of complications. Collaboration between healthcare providers from different specialties, including endocrinology, nephrology, and urology, may be necessary for comprehensive management of DI.

Badges
Science topic

More Indunil Karunarathna's questions See All

Detection and Identification of Amanitins in the Wood-Rotting Fungi Galerina fasciculata andGalerina helvoliceps

Dear all, Can anyone help me to contact the corresponding author of the paper " Muraoka, S., Fukamachi, N., Mizumoto, K., & Shinozawa, T. (1999). Detection and Identification of Amanitins in...

01 January 1970 6,517 3 View

Edible mushrooms and their cultivation

Hi All, Does anyone have the PDF of following book? Chang, S. T.; Miles, P. G. (1989). Edible mushrooms and their cultivation. Edible Mushrooms and Their Cultivation, 345. Thanks

01 January 1970 7,851 1 View

Can two EC50 values with different hill slopes be compared?

Hello, I fit a classical dose response curve Y=Bottom + (Top-Bottom)/(1+10^((LogEC-X)*HillSlope)) to my data (not related to inhibitors etc). The model I use is purely qualitative but it fits...

23 February 2021 8,155 5 View

Is this grounds for theophylline toxicity even though her plasma is within the therapeutic range? if it is, how is that possible?

A patient was given 300 mg Theophylline taken twice a day for the treatment of her bronchial asthma and has a positive clinical response. She has been compliant in taking her medication however,...

09 February 2021 3,489 3 View

Difference between assessing EC50 in presence of physiological levels of human serum albumin and alpha1 acid glycoprotein vs. % human serum?

01 February 2021 1,825 1 View

How can we increase awareness about Covid 19 prevention in our city among the local population?

The general public must be made aware of the mode of transmission, presenting symptoms and the measures that can be undertaken to prevent the spread of infection. Few options- Media, Webinars...

03 January 2021 3,538 13 View

Are the receptor proteins on the surface of infected cells will increase or decrease the susceptibility of antivirals?

22 December 2020 3,242 4 View

How to convert Terapeutic Human Doses to Cell Experimentation Doses?

"Toxicological evaluations revealed that Cur is found to be pharmacologically safe, even up to 12 g per day, as reported by several animal studies and in phase-I clinical trials Similarly,...

07 December 2020 3,012 1 View

How to increase presynaptic neurotransmitter release artificially?

I would like to pharmacologically increase presynaptic neurotransmitter release in mice CNS in vivo (through the extracellular micro-infusion of a compound). Which strategy would you recommand?...

02 November 2020 5,645 3 View

No title

30 October 2020 961 3 View

Poly ICLC or Poly IC structure for docking ?

I want to do docking of Poly ICLC with protein. But, unfortunately there is no crystal structure for Poly ICLC or poly IC. Poly ICLC is a complex of Poly IC, poly lysine, and...

24 September 2020 6,107 1 View

Journals accepting book reviews in Pharmacy field (Pharmacology)?

I had published books as a part of my research interest related to pharmacy field (Pharmacology). Now, I am interested to submit books to review in academic journals (Book review publish). Can any...

19 September 2020 1,666 2 View